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ABSTRACT 
We aimed to compare the results of pars plana vitrectomy (PPV) with internal limiting membrane (ILM) 
peeling, an alternative therapeutic strategy, with those of medical treatment for chronic macular edema. 
We conducted a review of the literature on the microscopic, anatomical, and functional reasons for 
performing PPV with ILM peeling in patients with diabetic macular edema (DME). We searched the PubMed 
database for articles published between 2000 and 2017. We used the medical subject heading “vitrectomy 
diabetic macular edema” and the keywords “diabetic macular edema”, “internal limiting membrane 
peeling”, “pars plana vitrectomy”, “diabetic retinopathy”, and “optical coherence tomography”. Analysis of 
the literature revealed that cytokines, vascular endothelial growth factor, reactive oxygen species (ROS), 
and advanced glycation end-products (AGEs) play a unique role in DME. The vitreous cavity serves as a 
physiological reservoir for all inflammatory molecules. AGE receptors are localized at the footplates of 
Müller cells and the external limiting membrane (ELM). The footplates of Müller cells are in contact with 
the ILM, which suggests that they might be responsible for the structural damage (i.e., thickening) observed 
in the ILM of patients with DME. Therefore, PPV could allow a reduction of cytokines and pro-inflammatory 
molecules from the vitreous cavity. ILM peeling could eliminate not only the physical traction of a 
thickened structure, but also the natural reservoir of AGEs, ROS, and inflammatory molecules. PPV with ILM 
peeling is a surgical option that should be considered when treating patients with chronic DME. 
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INTRODUCTION
Diabetic macular edema (DME) is one of the most 
common complications of diabetic retinopathy (DR) and 
is a frequent cause of sudden impairment of visual acuity 
(VA). The incidence of DME ranges from 14% to 29% in 
patients with DR. According to the Wisconsin 
Epidemiologic Study of Diabetic Retinopathy, the 
estimated prevalence of DME after 20 years following a 
diagnosis of diabetes mellitus (DM) is 12%–29% in 
patients with DM type 1 and 2 [1]. DME represents a 
severe threat to public health. The World Health 
Organization (WHO) Global Report of Diabetes 2016 
indicates that Mediterranean East, South East Asia, and 
the American continent are the most affected regions in 
the world [2]. The cost of the disease varies according to 
the country. However, according to data from countries 
in the European Union, the annual cost is EURO 777 to 
EURO 7153, depending on the need for different 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2017; 6(4)  
 
137 SURGICAL VS MEDICAL TREATMENT FOR DIABETIC MACULAR EDEMA  
treatments, such as laser or anti-vascular endothelial 
growth factor (VEGF) drugs [3].  
The aim of this study was to review scientific evidence 
for considering pars plana vitrectomy (PPV) as a 
treatment for DME.  
MATERIALS AND METHODS 
We conducted a review of the literature about the 
microscopic, anatomical, and functional reasons 
supporting the use of PPV with internal limiting 
membrane (ILM) peeling as a treatment option for DME. 
We searched the PubMed database for articles published 
between 2000 and 2017. We used the medical subject 
heading “pars plana vitrectomy diabetic macular edema” 
and the keywords “diabetic macular edema,” “internal 
limiting membrane peeling,” “pars plana vitrectomy,” 
“diabetic retinopathy,” and “optical coherence 
tomography.” As inclusion criteria, we used clinical trials, 
review, systematic review, case reports, clinical studies, 
and multicenter studies as filters. Exclusion criteria were 
repeated papers, incomplete information, or missing 
data. If no statistical analysis of data was reported, we 
focused on molecular analysis and clinical evidence 
reported in the surgical management of DME. 
RESULTS  
A searched was performed in PubMed database, and 190 
papers were found with PPV and DME. After filters and 
key words were applied, 67 papers were retained; 
however, many of these were discarded because of 
incomplete data, confusing evidence, or repeated 
information. We finally selected 22 publications for this 
review, which are summarized in Table 1. 
There is a close association between DME and diabetic 
metabolic control. A higher level of glycosylated 
hemoglobin, high systolic blood pressure, and borderline 
proteinuria are all risk factors for DME [3]. The 
pathophysiology of this condition is complex, and some 
aspects are still being debated. The oxidative stress 
caused by multiple inflammatory cytokines is believed to 
be a key factor for vascular damage [4]. Chronic 
hyperglycemia causes oxidative stress by inducing the 
formation of advanced glycation end-products (AGEs) 
and non-enzymatic glycosylation of proteins. AGEs can 
cross-link the amino-termini of proteins, lipids, and DNA, 
leading to modification of their tertiary structure and 
function. They can also activate intercellular adhesion 
molecule-1 (ICAM-1), causing damage to cellular 
membranes and endothelia by increasing transcription 
factors, such as nuclear factor kappa B [5]. In addition, 
alteration in the expression of adhesion molecules and 
release of pro-inflammatory cytokines induce the 
upregulation of other proteins. such as adhesion 
molecule-1 (E-selectin) and vascular cell adhesion 
molecule-1 (VCAM-1), which in conjunction with ICAM-1, 
induce leukostasis and further cell damage [6]. The 
formation of reactive oxygen species (ROS) has also been 
implicated in the pathophysiology of DME. ROS cause 
oxidative damage to the lipid bilayer of cell membranes 
by lipid peroxidation [7]. Damage to specific cells, such as 
perivascular pericytes, induces microvessel occlusion and 
microaneurysm formation. The resulting hemodynamic 
dysfunction leads to abnormal autoregulation of the 
retinal blood flow and an imbalance in retinal 
metabolism homeostasis. The damage exerted on 
capillary-vessel basement membranes by ROS and AGEs 
induces an increase in the deposition of extracellular 
matrix components, which in turn further exacerbate 
hemodynamic dysfunction, thus impairing autoregulation 
[8-10].  
VEGF is a dimeric glycoprotein that has a fundamental 
role in pathological angiogenesis. Its concentration in the 
vitreous is increased exponentially in patients with DR 
[11]. VEGF-A has six major isoforms (121, 145, 165, 183, 
189, and 206) and three main membrane receptors 
(VEGFR-1, 2, and 3) [5]. In DME, VEGF can induce 
vasodilation of the retinal vessels, enhance vascular 
permeability, and activate endothelial cells [6]. VEGF also 
phosphorylates claudin-1, a protein that is present in the 
tight junctions of retinal endothelial cells. The protein is 
then downregulated and delocalized, leading to 
increased vascular permeability and retinal edema [12, 
13]. 
There is evidence that RD depends not only on the usual 
diet or glycemic levels, but also on a genetic background 
that promotes development of diabetes and its 
complications, and which varies across different 
populations [14]. Traditionally, DME is classified as focal 
or diffuse based on leakage patterns on fluorescein 
angiography (FA). More recently, optical coherence 
tomography (OCT) is used to provide in-depth 
information about tissue structure, which is essential for 
elaborate therapeutic strategies in DME [15]. The 
classification proposed by Kim et al. in 2006 describes 
five well-defined patterns of DME by OCT: diffuse retinal 
thickening, cystoid macular edema, serous retinal 
detachment (RD) without posterior hyaloidal traction 
(PHT), PHT without tractional RD, and PHT with RD [16] 
(Fig 1 A and B). OCT angiography (OCTA) is a new 
diagnostic device that allows the theoretical 
identification of the blood flow through retinal blood 
vessels [17]. Early reports have shown areas of decreased 
signal intensity that correlate well with areas of 
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intraretinal fluid accumulation on OCT. Areas of cystoid 
edema appear entirely devoid of flow with borders 
where there is no vascular flow surrounding the capillary 
meshwork [18].  
 
 
 
Table 1: Summary of the Most Relevant Data Regarding Pars Plana Vitrectomy and Diabetic Macular Edema from 2000 to 2017 
Year Author Type of Study Main Outcome 
2001 Augustin et al. Clinical Trial Oxidative metabolites are able to modulate growth activity via VEGF activity directly 
2002 Kumagai et al. Clinical Trial ILM peeling accelerates the absorption of edema in more severe DME without change in 
VA 
2005 Holeamp et al. Case Series Vitrectomy increases intraocular oxygen tension, which may lead to nuclear cataract 
formation 
2006 Stefánsson et al. Review Both laser and vitrectomy treatment help to increase inner retina oxygenation 
2009 Bhagat et al. Review Combined surgical and medical treatment is the best option to manage DME 
2009 Sakamoto et al. Retrospective Postoperative photoreceptor status of the fovea is closely related to the final VA 
2010 DRCR.Net et al. Clinical Trial Vitrectomy performed for DME and vitreomacular traction; retinal thickening was reduced 
in most eyes 
2010 Otani et al. Case Series OCT showed that the integrity of the external limiting membrane and inner and outer 
segments of the photoreceptors were more strongly correlated with VA 
2011 Deissler et al. Experimental VEGF 165 is mainly responsible for changes in cellular permeability in retinal endothelial 
cells 
2011 Yanyali et al. Case Series The integrity of the ELM and IS/OS lines was positively correlated with final visual acuity 
after PPV 
2012 Tamura et al. Case Series The ILM is thickened and numerous types of inflammatory cells are attached 
2012 Chhablani et al. Retrospective Preoperative evaluation of the ELM predicts vision improvement more accurately than the 
IS/OS junction 
2013 Koskela et al. CaseControl Elevated IL-6 and IL-8 levels in vitreous, but not in plasma, are evidence favouring local 
over systemic inflammation in PDR 
2013 Yamada et al. Clinical Trial Glycemic control may be important for retinal thickness after ocular surgery 
2013 Nizawa et al. CaseControl PPV either with or without preoperative treatments can significantly improve the BCVA 
and reduce the central macular thickness MT in patients with diffuse DME 
2014 Romano et al. Retrospective DME with intraretinal cysts larger than 390 µm should not be treated with vitrectomy with 
ILM peeling, because this may induce subfoveal atrophy 
2015 Kumagai et al. Clinical Trial PPV with or without peeling improves long term VA of DME 
2015 Bonnin et al. CaseControl Vitrectomized eyes are not different in terms of anatomical and visual outcomes in 
patients with or without tractional DME 
2016 Ichiyama et al. Clinical Trial Vitrectomy can be a useful treatment option for diffuse DME, particularly for eyes with 
subretinal fluid 
2017 Gonzalez-
Salinas et al. 
CaseControl Different VEGF polymorphisms could be related to grades of proliferative DR 
2017 Jackson et al. Systematic 
Review 
Vitrectomy produces structural and functional improvements in select eyes with DME, but 
the visual gains are not significantly better than with laser or observation. 
Abbreviations: Pars plana vitrectomy (PPV); internal limiting membrane (ILM); reactive oxygen species (ROS); advanced glycation end-
product (AGE); external limiting membrane (ELM); diabetic macular edema (DME); diabetic retinopathy (DR); visual acuity (VA); diabetes 
mellitus (DM); World Health Organization (WHO), vascular endothelial growth factor (VEGF); intercellular adhesion molecule-1 (ICAM-1); 
vascular cell adhesion molecule-1 (VCAM-1); vascular endothelial growth factor receptor (VEGFR); fluorescein angiography (FA); optical 
coherence tomography (OCT); posterior hyaloidal traction (PHT); optical coherence tomography angiography (OCTA); best-corrected 
visual acuity (BCVA); glial fibrillary acid protein (GFAP); inner segments/outer segments (IS/OS) 
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Figure 1: Optical coherence tomography images showing diffuse bilateral diabetic macular edema. 
Multiple hard exudates (hyperreflective dots) and vitreous macular adhesion. B. Hard exudates (hyperreflective dots), cystic macular 
spaces (black cysts), and serous retinal detachment. 
 
Nevertheless, the diagnostic value of this new technology 
is still debated, since issues such as image artifacts and 
hard-to-understand changes limit the clinical application 
of the results. 
Medical Treatment for DME 
Anti-angiogenic drugs that specifically target VEGF are 
the current standard of care for DME treatment. There 
are currently two approved anti-VEGF drugs 
(ranibizumab and aflibercept) and one open-label anti-
VEGF drug (bevacizumab), with more drugs to come in 
the near future (conbercept, bevasiranib, razumab, 
xlucane, etc.). Several studies sponsored by the National 
Institutes of Health, such as those conducted by the 
Diabetic Retinopathy Clinical Research Network 
(DRCR.net) [19], and studies sponsored by the 
pharmaceutical industry (RESOLVE, RESTORE, RIDE, RISE, 
and DAVINCI) demonstrate that, alone or in combination, 
anti-VEGF drugs are superior to laser, sham treatment, or 
intravitreal triamcinolone for the treatment of DME, with 
excellent security profiles [20-22]. However, it is 
important to highlight that patients with chronic DME 
will probably develop tachyphylaxis after years of 
intravitreal injections of anti-VEGF. Moreover, there are 
many cytokines as important as VEFG in DME [23]. In 
relapsing or chronic cases of DME, a treatment 
alternative is the intravitreal implant of dexamethasone. 
Dexamethasone is five times more powerful than 
triamcinolone and is more hydrophilic, which allows 
higher vitreous concentrations [24]. A 6-mm implant 
containing 700 mg of dexamethasone is placed in the 
eye, where the drug is slowly released into the vitreous 
cavity over a period of 6 months [25-27]. In clinical trials 
of difficult cases of DME, the implant has demonstrated 
to be an effective alternative, alone or in combination 
with anti-VEGF drugs, by improving central macular 
thickness, best-corrected visual acuity (BCVA), 
microperimetry results, and electrofunctional test results 
after treatment [28-31]. 
Surgical Treatment for DME 
Inflammatory cytokines, ROS, and AGEs play unique roles 
in DME. In patients with DR, the vitreous cavity serves as 
a physiological reservoir to all of the above-mentioned 
molecules. As the blood–retinal barrier becomes 
damaged with time, more pro-inflammatory cytokines 
and growth factors can gain access into this anatomical 
space. The accumulation of AGEs can destroy the 
vitreoretinal interface and induce neurovascular damage 
[5]. Moreover, accumulation of AGEs can also be found in 
the posterior vitreous cortex and ILM. AGE receptors 
have been found in the footplates of Müller cells and the 
external limiting membrane (ELM), suggesting that they 
might be responsible for the structural damage 
(thickening) observed in the ILM of patients with DME. 
Activation of AGEs may induce non-tractional cell-
mediated effects on adjacent retinal layers (from ILM to 
ELM, including the deep retinal capillary plexus) [5]. 
Finally, the accumulation of AGEs in the posterior 
vitreous cortex can increase the adhesion of the 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2017; 6(4)  
 
140 SURGICAL VS MEDICAL TREATMENT FOR DIABETIC MACULAR EDEMA  
posterior vitreous cortex to the ILM. The consequence is 
a thickened and taut posterior hyaloid cortex, which can 
be seen on slit lamp examination as a glittering taut 
membrane, and by FA and OCT imaging, as a firm 
attachment of the posterior hyaloid to the fovea with 
diffuse leakage in the macular area [5]. VEGF levels are 
substantially increased in the vitreous cavity of patients 
with DR. As retinal hypoxia increases, the concentration 
of VEGF also increases, inducing retinal 
neovascularization and capillary vasodilation [32-35]. 
Following PPV, vitreous oxygen content improves, and 
VEGF concentration decreases. This can potentially 
decrease vascular permeability and stimulate 
vasoconstriction with the concomitant reduction of the 
blood flow, hindering DME formation [36].
 
In addition, 
the peeling of the thickened ILM eliminates physical 
traction and removes AGEs from the vitreoretinal 
interface. In some cases, there is an associated epiretinal 
membrane and/or vitreoretinal traction, which can also 
be removed. In summary, there is strong evidence 
supporting the removal of the vitreous, the vitreous 
cortex, and the ILM in selected cases of DME.  
The identification of patients with DME that can possibly 
benefit from surgery is of uttermost importance [37-39]. 
A good metabolic control is essential. Patients with low 
levels of glycosylated hemoglobin have a greater 
likelihood of improved BCVA after PPV [40]. The integrity 
of the ELM, the myoid, and ellipsoid zones 
(interdigitation zone) has been mentioned in several 
studies as a possible predictive factor of visual 
improvement [37, 41]. Patients with DME and signs of 
retinal gliosis are associated with increased expression of 
glial fibrillary acid protein (GFAP) in Müller cells and 
astrocytes. GFAP has an essential role in cell adhesion 
through the cytoskeleton, surface receptors, and 
extracellular matrix. Surgeons must be aware of large 
intraretinal cysts and enlarged foveal avascular zones 
because, as Romano et al. demonstrated, patients with 
those characteristics have a higher risk of subfoveal 
atrophy and visual deterioration [42]. The identification 
of the morphological pattern of DME by OCT, as 
described by Ichiyama et al., could also be a prognostic 
factor for visual improvement. Patients with sponge-like 
diffuse retinal thickening are the least likely to improve 
BCVA significantly after PPV [43]. 
Clinical Evidence Supporting PPV as a Treatment Option 
for DME 
In 2002, Kumagai et al. published the results of PPV in 
the treatment of DME. The study reported a 90% 
reduction of DME, with or without ILM peeling. They 
discussed that ILM removal might accelerate the 
resolution of the edema in more severe cases, but no 
statistical difference in VA was observed [44]. In another 
study, Kumagai et al. treated patients with non-tractional 
DME with PPV, dividing the population into two groups: 
ILM peeling and no ILM peeling. Both groups achieved a 
statistically significant reduction in central macular 
thickness during the follow-up. However, the role of ILM 
peeling was still unclear, since it did not affect the results 
conclusively [45]. The results were similar to those of the 
study by Bonnin et al., in which patients with tractional 
and non-tractional DME were treated with PPV. Both 
groups had improved BCVA at the end of the follow-up 
period, but the authors failed to demonstrate any 
anatomical or functional differences between the two 
groups [46]. Nizawa et al. explored the effect of PPV in 
patients with diffuse DME, with or without previous 
treatments (bevacizumab, triamcinolone, or micropulse 
laser). BCVA was improved in both groups, and there was 
no significant difference between them [47]. A study 
from the DRCR.net reported that 68% of the participants 
achieved at least a 50% reduction in edema; 38% (95% 
confidence interval [CI]: 28%–49%) had improved BCVA 
(more than 10 letters) and 22% had deteriorated BCVA 
(less than 10 letters). Complications included vitreous 
hemorrhages, RD, and elevated intraocular pressure 
(IOP) at low rates [48].  
As in any other scenario, PPV for DME patients is not 
without risk and complications. However, the incidence is 
similar to any other PPV surgical event. The most 
frequent intraoperative complication is retinal breaks 
(7.08%) and iatrogenic tears (0.68%). During the follow-
up period, patients can experience cataract formation 
(2.56%), elevation of the IOP (5.19%), epiretinal 
membrane development (3.27%), vitreous hemorrhages 
(2.43%), and neovascular glaucoma (1.06%) [49]. 
CONCLUSIONS 
In summary, PPV with ILM peeling can be considered a 
treatment option for chronic DME. The vitreous cavity in 
patients with DME is rich in cytokines and pro-
inflammatory molecules such as VEGF; decreasing their 
levels could reduce their effects on retinal layers and 
increase oxygen levels in the vitreous. ILM peeling can 
not only eliminate physical traction, but can also remove 
the natural reservoir of AGEs, ROS, and inflammatory 
molecules. However, PPV is not a risk-free treatment, 
with retinal breaks and elevation of IOP being the most 
frequent adverse effects. In future, multicenter clinical 
trials are needed to understand the microscopic changes 
that occur in the ILM of patients with diabetes as well as 
the rate of anatomical and functional success. A 
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prospective follow-up of those patients should provide 
further knowledge about DME recurrence. 
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